Initial Statement of Beneficial Ownership (3)
June 19 2017 - 7:38AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lynch Ryan
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/15/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
CONCERT PHARMACEUTICALS, INC. [CNCE]
|
(Last)
(First)
(Middle)
C/O CONCERT PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, SUITE 500
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
PFO, PAO /
|
(Street)
LEXINGTON, MA 02421
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Employee Stock Option (right to buy)
|
(1)
|
6/11/2024
|
Common Stock
|
6700
|
$9.46
|
D
|
|
Employee Stock Option (right to buy)
|
(2)
|
1/6/2026
|
Common Stock
|
2400
|
$16.85
|
D
|
|
Employee Stock Option (right to buy)
|
(3)
|
1/3/2027
|
Common Stock
|
4000
|
$10.97
|
D
|
|
Explanation of Responses:
|
(1)
|
Twenty five percent (25%) of the shares subject to this option vested on June 12, 2015, and the option vested and will continue to vest in equal quarterly installments thereafter, until June 12, 2018, at which time this option will be fully vested.
|
(2)
|
This option vests in sixteen equal quarterly installments beginning on April 7, 2016.
|
(3)
|
This option vests in sixteen equal quarterly installments beginning on April 4, 2017.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Lynch Ryan
C/O CONCERT PHARMACEUTICALS, INC.
99 HAYDEN AVENUE, SUITE 500
LEXINGTON, MA 02421
|
|
|
PFO, PAO
|
|
Signatures
|
/s/Ryan Lynch
|
|
6/19/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024